TITLE:
Psoriatic skin lesions induced by tumor-necrosis-factor-alpha-therapy
AUTHORS:
Antonia Cosima Faul, Christian Folwaczny, Birgit Angela Aigner, Rüdiger Hein, Johannes Ring, Sabine Gisela Plötz
KEYWORDS:
Infliximab; Psoriasis; TNFα Inhibitors; Crohn’s Disease; Ankylosing Spondylitis; Side Effects
JOURNAL NAME:
Case Reports in Clinical Medicine,
Vol.2 No.1,
March
25,
2013
ABSTRACT: A 46-year-old, caucasian woman suffering from Crohn’s disease and a 35-year-old
woman suffering from ankylosing spondylitis were treated with the TNFα blocker infliximab and developed psoriasiform
skin lesions. The pathophysiology of this paradoxical clinical response as a newly
recognized adverse effect of TNFα antagonists
is unknown. According to the literature, this type of newly triggered psoriasis
may occur any time after initiation of TNFα antagonist therapy and responds to classic antipsoriatic treatment. The phenomenon warrants attention, especially when
considering anti-TNFα treatment in various
skin diseases besides psoriasis.